Press Releases

Tuesday, February 18, 2014

Mapi Pharma Granted United States Patent Covering the Process for the Preparation of Fingolimod for Multiple Sclerosis

The patent covers intermediate compounds and processes for the preparation of Fingolimod

Mapi Pharma Ltd. (“Mapi” or the “Company”), a developer of high-barrier to entry and high value-added generic drugs that include complex active pharmaceutical ingredients (“APIs”), formulations and life cycle management (“LCM”) products that target large markets, announced today that it was granted a United States patent covering the process for the preparation of Fingolimod, a drug currently marketed by Novartis under the trade name Gilenya. 
Read More...
 

Tuesday, June 18, 2013

Mapi Pharma Granted United States Patent for Pain Relief Medication “Tapentadol”

The patent covers the process and preparation of Tapentadol for the treatment of moderate to severe-acute pain

Mapi Pharma Ltd. (Mapi), developer of complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, and finished dosage forms based on selected drug delivery systems, announced today that the company has been granted a United States patent for Tapentadol. Tapentadol is indicated in the US and Europe for the oral treatment of moderate-to-severe acute pain.
Read More...


Monday, May 6, 2013

Mapi Pharma Granted United States Patent  covering Glatiramer Depot for Multiple Sclerosis

The patent covers a long acting depot formulation that enables monthly rather than daily treatment regimens for MS patients

Mapi Pharma Ltd. (Mapi), developer of complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, and finished dosage forms based on selected drug delivery systems, announced today that the company has been granted a United States patent for a long acting depot formulation of glatiramer acetate. The formulation is under development as a once-a-month treatment for Multiple Sclerosis (MS). The existing glatiramer acetate dosage form on the market today requires daily administrations (by injection).
Read More...